Biotech | August 10, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Company working on COVID vaccine INO 4800
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
The company posted net profit of Rs.34.24 crores for the period ended June 30, 2020.
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
PAT rises to Rs 195.76 crore
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
